Cancer Research Cancer Health Disparities Conference 2009  AM No Date
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martínez, N.
Right arrow Articles by Piris, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martínez, N.
Right arrow Articles by Piris, M. A.
[Cancer Research 63, 8226-8232, December 1, 2003]
© 2003 American Association for Cancer Research


Regular Articles

The Molecular Signature of Mantle Cell Lymphoma Reveals Multiple Signals Favoring Cell Survival

Nerea Martínez1, Francisca I. Camacho1, Patrocinio Algara3, Antonia Rodríguez1, Ana Dopazo2, Elena Ruíz-Ballesteros3, Paloma Martín4, Jose A. Martínez-Climent5, Javier García-Conde5, Javier Menárguez6, Fernando Solano7, Manuela Mollejo3 and Miguel A. Piris1

1 Molecular Pathology Program and
2 Biotechnology Program, Centro Nacional de Investigaciones Oncológicas, Madrid;
3 Department of Genetics and Pathology, Hospital Virgen de la Salud, Toledo;
4 Department of Pathology, Hospital Ramón y Cajal, Madrid;
5 Department of Hematology and Medical Oncology, Hospital Clínico, University of Valencia, Valencia;
6 Department of Pathology, Hospital General Universitario Gregorio Marañón, Madrid; and
7 Department of Hematology, Hospital Nuestra Señora del Prado, Talavera de la Reina, Toledo, Spain

Mantle cell lymphoma (MCL) is a prototypical neoplastic disease in which a common cytogenetic alteration, t11;14, leading to cyclin D1 overexpression, is associated with other changes that need to be considered in an explanation of the clinical, morphological, and molecular variability of this disease. Using a cDNA microarray (Oncochip-CNIO) containing clones for 6386 cancer-related genes, we have analyzed the expression profiles of a series of 38 cases. After normalization with the expression profiling of sorted mantle zone lymphocytes, we have related the findings to conventional clinical and molecular variables, including immunoglobulin variable heavy chain somatic mutation, blastoid cytology, increased proliferation, and long-term survival.

MCL signature (446 genes) includes genes involved in apoptosis, cell cycle, signal transduction, and cell structure. Especially striking was the presence of multiple concurrent alterations in the tumor necrosis factor and nuclear factor {kappa}B pathway, and the overexpression of IL10R and SPARC genes. We also identified a molecular signature for the presence of immunoglobulin variable heavy chain somatic mutation, which includes a number of genes potentially relevant in cancer (CDC14A, ras, and others). Signatures for proliferation and blastoid cytology were also found.

An integrated analysis of these data yields a gene-expression based survival predictor (26 genes grouped into two clusters), which distinguishes half of the patients with a survival probability of 52% at 5 years. The predictive model has been confirmed by cross-validation.

In conclusion, MCL seems to combine a disease-specific signature and different sets of genes of which the expression is associated with key clinical, molecular, and immunophenotypical events.




This article has been cited by other articles:


Home page
BloodHome page
P. Gelebart, M. Anand, H. Armanious, A. C. Peters, J. Dien Bard, H. M. Amin, and R. Lai
Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma
Blood, December 15, 2008; 112(13): 5171 - 5179.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
J. Wu, H. P. Cho, D. B. Rhee, D. K. Johnson, J. Dunlap, Y. Liu, and Y. Wang
Cdc14B depletion leads to centriole amplification, and its overexpression prevents unscheduled centriole duplication
J. Cell Biol., October 14, 2008; 181(3): 475 - 483.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
L. Tracey, M. Aggarwal, M. Garcia-Cosio, R. Villuendas, P. Algara, M. Sanchez-Beato, A. Sanchez-Aguilera, J. F. Garcia, A. Rodriguez, F. I. Camacho, et al.
Somatic hypermutation signature in B-cell low-grade lymphomas
Haematologica, August 1, 2008; 93(8): 1186 - 1194.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Dal Col, P. Zancai, L. Terrin, M. Guidoboni, M. Ponzoni, A. Pavan, M. Spina, S. Bergamin, S. Rizzo, U. Tirelli, et al.
Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma
Blood, May 15, 2008; 111(10): 5142 - 5151.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
F. Morschhauser, J. F. Seymour, H. C. Kluin-Nelemans, A. Grigg, M. Wolf, M. Pfreundschuh, H. Tilly, J. Raemaekers, M. B. van 't Veer, N. Milpied, et al.
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma
Ann. Onc., February 1, 2008; 19(2): 247 - 253.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
N. Kawamata, J. Chen, and H. P. Koeffler
Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells
Blood, October 1, 2007; 110(7): 2667 - 2673.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. J. Ford, L. Shen, Y. C. Lin-Lee, L. V. Pham, A. Multani, H.-J. Zhou, A. T. Tamayo, C. Zhang, L. Hawthorn, J. K. Cowell, et al.
Development of a murine model for blastoid variant mantle-cell lymphoma
Blood, June 1, 2007; 109(11): 4899 - 4906.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M.-A. Lyu, L. H. Cheung, W. N. Hittelman, J. W. Marks, R. C.T. Aguiar, and M. G. Rosenblum
The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA
Mol. Cancer Ther., February 1, 2007; 6(2): 460 - 470.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
J. Madoz-Gurpide, P. Lopez-Serra, J. L. Martinez-Torrecuadrada, L. Sanchez, L. Lombardia, and J. I. Casal
Proteomics-based Validation of Genomic Data: Applications in Colorectal Cancer Diagnosis
Mol. Cell. Proteomics, August 1, 2006; 5(8): 1471 - 1483.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Sanchez-Aguilera, C. Montalban, P. de la Cueva, L. Sanchez-Verde, M. M. Morente, M. Garcia-Cosio, J. Garcia-Larana, C. Bellas, M. Provencio, V. Romagosa, et al.
Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma
Blood, July 15, 2006; 108(2): 662 - 668.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
S. Ek, U. Andreasson, S. Hober, C. Kampf, F. Ponten, M. Uhlen, H. Merz, and C. A. K. Borrebaeck
From Gene Expression Analysis to Tissue Microarrays: A Rational Approach to Identify Therapeutic and Diagnostic Targets in Lymphoid Malignancies
Mol. Cell. Proteomics, June 1, 2006; 5(6): 1072 - 1081.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. Ruiz-Ballesteros, M. Mollejo, A. Rodriguez, F. I. Camacho, P. Algara, N. Martinez, M. Pollan, A. Sanchez-Aguilera, J. Menarguez, E. Campo, et al.
Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis
Blood, September 1, 2005; 106(5): 1831 - 1838.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. Rubio-Moscardo, J. Climent, R. Siebert, M. A. Piris, J. I. Martin-Subero, I. Nielander, J. Garcia-Conde, M. J. S. Dyer, M. J. Terol, D. Pinkel, et al.
Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome
Blood, June 1, 2005; 105(11): 4445 - 4454.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
N. Martinez, M. Sanchez-Beato, A. Carnero, V. Moneo, J. C. Tercero, I. Fernandez, M. Navarrete, J. Jimeno, and M. A. Piris
Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients
Mol. Cancer Ther., May 1, 2005; 4(5): 814 - 823.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
I. M. Ghobrial, D. J. McCormick, S. H. Kaufmann, A. A. Leontovich, D. A. Loegering, N. T. Dai, K. L. Krajnik, M. J. Stenson, M. F. Melhem, A. J. Novak, et al.
Proteomic analysis of mantle-cell lymphoma by protein microarray
Blood, May 1, 2005; 105(9): 3722 - 3730.
[Abstract] [Full Text] [PDF]


Home page
aacredbookHome page
Q. Gong, A. C. Chan, and F. Martin
Contributions of Circulatory Dynamics and Cellular Microenvironment in Anti-CD20 mAb Immunotherapy
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 160 - 165.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Rodriguez, N. Martinez, F. I. Camacho, E. Ruiz-Ballesteros, P. Algara, J.-F. Garcia, J. Menarguez, T. Alvaro, M. F. Fresno, F. Solano, et al.
Variability in the Degree of Expression of Phosphorylated I{kappa}B{alpha} in Chronic Lymphocytic Leukemia Cases With Nodal Involvement
Clin. Cancer Res., October 15, 2004; 10(20): 6796 - 6806.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.